{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T19:28:41Z","timestamp":1786390121127,"version":"build-2736575974"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Erythrodermic psoriasis (EP) is characterized by generalized erythema and desquamation affecting more than 75% of body surface area and usually accompanied by systemic symptoms. The triggers are medication withdrawal, drugs reactions, and systemic infections including coronavirus disease 2019 (COVID-19). A 46-year-old man with plaque psoriasis suffered from EP following the sudden discontinuation of medications. He was diagnosed with COVID-19 one month before erythroderma appeared. The body surface area involvement was 96% and psoriasis area severity index was 49.8. His general condition and laboratory examination were within normal limits. He was treated with cyclosporine-A for one month after being healed from COVID-19 with significant improvement. Excessive production of proinflammatory cytokines in COVID-19 plays a role in the pathogenesis of psoriasis. This condition should be managed appropriately to minimize the complication. Cyclosporine-A is the first-line therapy for EP because of its effectiveness and good safety profile. It is also shown a beneficial effect in COVID-19 infection\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.5415\/apallergy.2022.12.e16","type":"journal-article","created":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T22:27:46Z","timestamp":1650839266000},"page":"e16","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Erythrodermic psoriasis in post-coronavirus disease 2019 patient"],"prefix":"10.5415","volume":"12","author":[{"given":"Irwan Saputra","family":"Batubara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Windy Keumala","family":"Budianti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","container-title":["Asia Pacific Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/apallergy.org\/pdf\/10.5415\/apallergy.2022.12.e16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/apallergy.org\/DOIx.php?id=10.5415\/apallergy.2022.12.e16","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.5415\/apallergy.2022.12.e16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T18:44:09Z","timestamp":1786387449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.5415\/apallergy.2022.12.e16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.5415\/apallergy.2022.12.e16","relation":{},"ISSN":["2233-8276"],"issn-type":[{"value":"2233-8276","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}